Recently, the chemokine receptor XCR1 has been found to be exclusively expressed on a subset of dendritic cells (DCs) known to excel in antigen cross-presentation. The impact of this chemokine receptor on DC biology can only be understood through combining the available knowledge on the XCR1 receptor, its chemokine ligand XCL1, and the current information on the function of DCs expressing XCR1.

The chemokine ligand XCL1 has been cloned independently by three groups, by Kelner et al. ([@B25]) as "lymphotactin" from murine immature thymocytes, by Müller et al. ([@B28]) as "ATAC" ("activation-induced, T cell-derived, and chemokine-related molecule") from two-signal activated human T cells, and by Yoshida et al. ([@B39]), who identified "single cysteine molecule-1" ("SCM-1," huXCL1) in PHA-stimulated human PBMC. The latter group later also found a second human gene, termed *SCYC2* (Yoshida et al., [@B40]), which encodes huXCL2, a protein differing only in amino acids 7 and 8 from the originally identified SCM-1 molecule, redesignated to SCM-1α. Interestingly, a gene corresponding to human *SCYC2/XCL2* has never been identified in the mouse. Dorner et al. ([@B10]) purified human ATAC, determined its mature protein form, and demonstrated that it is secreted as a partially glycosylated 93 aa protein with a calculated *M~r~* of 10.3 kDa. Mature human ATAC corresponds in its sequence to SCM-1α, and is 61.4% identical and 84% similar (NCBI blastp) to murine lymphotactin. Collectively, these three groups thus defined the nature of murine XCL1 and human XCL1 (SCM-1α)/XCL2 (SCM-1β).

The generation of mAb specific for murine ATAC/XCL1 provided the first information on the biological context of XCL1 secretion. *In vitro* activated murine NK cells, Th1-polarized CD4^+^ T cells, and CD8^+^ T cells were found to co-secrete ATAC/XCL1 with IFN-γ, MIP-1α, MIP-1β, and RANTES (Dorner et al., [@B12]), prototypical components of the Th1 immune defense (Moser and Loetscher, [@B27]). Further, the same co-secretion pattern was observed *in vivo* by NK cells in the early phase, and by antigen-specific CD8^+^ T cells in the later adaptive phase of murine listeriosis (Dorner et al., [@B12]), a disease in which the intracellular pathogen is cleared by a Th1-type immune reaction (Pamer, [@B30]). Together, these expression data strongly indicated the involvement of ATAC/XCL1 in the Th1 immune defense, but did not yet provide a mechanistic model of ATAC/XCL1 action.

The function of XCL1 remained unclear for many years. Kelner et al. ([@B25]) reported in their original publication that their newly identified protein induced chemotaxis of a variety of lymphocytes, hence their designation "lymphotactin." In the years following the cloning of lymphotactin/ATAC/SCM-1, a plethora of reports on the chemotactic action of XCL1 was published, both in the human and the mouse. These, as it later turned out, erroneous reports, claimed chemotaxis on T cells, B cells, NK cells, neutrophils, and other cell types (listed in Supplemental Table S1 of Dorner et al., [@B11]). Only few groups reported that they failed to observe any chemotaxis using a broad array of cell types (Bleul et al., [@B4]; Dorner et al., [@B10]; Johnston et al., [@B21]).

A major step forward was the identification of the receptor for XCL1 by the group of Yoshie. They matched a previously cloned human orphan G protein-coupled receptor GPR5 (Heiber et al., [@B19]) with the orphan human chemokines SCM-1α/XCL1 and SCM-1β/XCL2, employing binding and functional assays (Yoshida et al., [@B38]). Further work also indicated that GPR5, later officially designated XCR1, is the only receptor for XCL1 (Yoshida et al., [@B38]; Shan et al., [@B34]).

Usually, the identification of a receptor for a chemokine strongly facilitates the elucidation of the biological role of a given chemokine-receptor system, but not in this case. Since a XCR1-specific mAb was not available at that time, the detection of XCR1 expression in tissues had to be done by RT-PCR. The original description of the murine XCR1 gene assumed the existence of only a single-exon coding for XCR1 (Yoshida et al., [@B41]), so detection of XCR1 mRNA had to rely on a "single-exon" RT-PCR, a system highly prone to false positive results. As a result, more than a dozen publications reported the expression of XCR1 in a great variety of cell types, all of which turned out to be incorrect (listed in Supplemental Table S2 of Dorner et al., [@B11]).

The breakthrough regarding the expression of XCR1 came from studies employing poly (A) RNA for detection of XCR1 by RT-PCR and the recognition that the murine XCR1 gene contains two exons, allowing the use of an "intron-spanning" RT-PCR. This approach revealed that XCR1 mRNA is selectively expressed in "conventional" DCs, and not in resting or activated T cells, B cells, NK cells, or plasmacytoid DCs (pDCs). A more detailed analysis showed that only CD8^+^ DCs and a small proportion of CD8^−^ DCs express XCR1 mRNA (Dorner et al., [@B11]). These expression studies were corroborated by experiments using a reporter mouse, in which *lacZ* is expressed under the control of the XCR1 promoter. Whole-body histological analysis of this reporter mouse yielded signals compatible with the notion that XCR1 is exclusively expressed in DCs and not in other cells. In the spleen, the XCR1 signal was associated with CD8^+^ DCs in the red pulp and in T cell zones (Dorner et al., [@B11]; Crozat et al., [@B7]). In lymph nodes, XCR1 gene expression was identified in paracortical areas and subcapsular sinuses (Dorner et al., [@B11]) and was found to be highly associated with CD103 expressed by migratory DCs (Crozat et al., [@B8]).

Functional studies yielded results congruent with the obtained XCR1 receptor expression profile. XCL1 induced strong chemotaxis of murine CD8^+^ DCs, but not of other DC subtypes, T cells, B cells, or NK cells (Dorner et al., [@B11]). These experiments thus for the first time clearly defined XCL1 as a chemokine and revealed an unusually restricted target population, the CD8^+^ DCs. In a series of experiments, the function of XCR1 and its chemokine ligand was then tested *in vivo*. When antigen was targeted to APC via DEC-205 in mice, adoptively transferred CD8^+^ OT-I T cells became activated by the cross-presented antigen and started to secrete XCL1. Further, studies employing XCL1 gene-deficient mice revealed that XCL1 optimizes the expansion and survival of these OT-I CD8^+^ T cells and their subsequent differentiation into cytotoxic cells. Collectively, this study demonstrated the involvement of the XCL1--XCR1 axis in the dialog of CD8^+^ T cells with CD8^+^ DCs on their way to become cytotoxic T cells (Dorner et al., [@B11]).

CD8^+^ DCs in the mouse spleen are part of the "resident" DC population, which make up the large majority of splenic DCs. Resident DCs take up antigen locally and present it to T cells "on site." Resident DCs, which all express the CD11c cell surface protein, have been classically subdivided into CD4^+^ DCs (CD11b^hi^ CD4^+^ CD8^−^ CD205^lo^, around 70% of splenic DCs), CD8^+^ DCs (CD11b^lo^ CD8^+^ CD205^hi^, 20%), and DN DCs (CD11b^hi^ CD4^−^CD8^−^ CD205^lo^, 10%; Vremec et al., [@B36]). In the past, resident CD8^+^ DCs have been consistently implicated in antigen cross-presentation, in which exogenous antigen is not "classically" presented in the context of MHC-class II, but instead shunted to the MHC-class I pathway (den Haan et al., [@B9]; Shortman and Heath, [@B35]).

The correlation of XCR1 expression with CD8^+^ DCs was not perfect, with only 70--85% of CD8^+^ DCs showing the XCR1 driven *LacZ*-reporter signal, but also 2--8% of DN DCs (Dorner et al., [@B11]). These data could be fully reproduced with a mAb to murine XCR1 (unpublished data), raising questions about the functional role of the 20--25% of CD8^+^ DCs not expressing XCR1, and the 2--8% of DN DCs positive for XCR1, but not expressing CD8. Of interest in this context, CFSE-labeled allogeneic 300--19 pre-B cells injected i.v. were essentially only taken up by XCR1^+^ DCs, while CD8^+^ DCs lacking XCR1 and other DCs played a negligible part (unpublished data).

The uptake studies were complemented by tests for antigen cross-presentation. Soluble ovalbumin (OVA) was injected i.v., and 14 h later CD8^+^ XCR1^+^, CD8^−^ XCR1^+^ (corresponding to the XCR1^+^ DN DC subset), CD8^+^ XCR1^−^, and CD8^−^ XCR1^−^ DCs were highly purified from spleens and co-cultured with OT-I *in vitro*. In this classical assay for antigen cross-presentation, CD8^+^ XCR1^+^ and CD8^−^ XCR1^+^ DCs presented soluble OVA clearly better than CD8^+^ XCR1^−^ and CD8^−^ XCR1^−^ DCs (unpublished data). When the same experiment was performed with cell-associated antigen (300--19 cells transfected with OVA), splenic CD8^+^ XCR1^+^, and CD8^−^ XCR1^+^ DCs excelled in antigen cross-presentation, whereas CD8^+^ XCR1^−^ and CD8^−^ XCR1^−^ DCs fully failed (unpublished data). Both assays with soluble and cell-associated antigen thus demonstrated the superior capacity of the XCR1^+^ DC populations to cross-present antigen, irrespective of CD8 expression on their surface.

When these functional studies were followed by extensive phenotyping of these four DC populations, the XCR1^+^ CD8^+^ DCs appeared homogeneous and very similar to XCR1^+^ CD8^−^ DCs. On the other hand, both XCR1^−^ CD8^+^ DCs and XCR1^−^ CD8^−^ DCs exhibited a quite different surface phenotype (unpublished data). When combining the phenotypic analysis of the various DC subsets with their ability to cross-present antigen, it becomes apparent that the current classification of DCs into CD8^+^ DCs, CD4^+^ DCs and DN DCs may no longer be useful. Instead, splenic XCR1^+^ DCs appear as a rather homogeneous population set apart from the XCR1^−^ DCs. The XCR1^−^ DC population, on the other hand, may possibly be further subdivided, e.g., based on the expression of the fractalkine receptor, as suggested recently by Bar-On et al. ([@B2]). More functional data with DCs from other lymphoid organs will be necessary to further characterize the XCR1^+^ and XCR1^−^ DC populations. However, what emerges from the current studies is the close correlation of XCR1 expression with the ability of DCs to cross-present antigen. The XCL1--XCR1 axis thus appears as an integral part of the antigen cross-presentation machinery.

How can we imagine the contribution of the XCL1--XCR1 system to the defense of pathogens? From the few *in vivo* studies available it is clear that NK cells, and possibly also other cells of the innate immune system, secrete this chemokine early upon infection with certain pathogens like *Listeria* or MCMV (Dorner et al., [@B12], [@B13]). When NK cells release XCL1, they co-release this chemokine with a set of other cytokines and chemokines, most notably IFN-γ, as part of a Th1-type of defense (Dorner et al., [@B12], [@B14], [@B13]). It seems likely that secretion of XCL1 under these circumstances facilitates the communication of NK cells with XCR1^+^ DCs (and vice versa, Figure [1](#F1){ref-type="fig"}). It is interesting to note that in the adaptive phase of the immune response activated CD8^+^ T cells communicate with XCR1^+^ DCs by secreting the same array of XCL1-associated cytokines and chemokines (Dorner et al., [@B12]). XCR1^+^ DCs are the ideal communication partners for CD8^+^ T cells, since they optimally cross-present antigen and integrate any inflammatory signals, so CD8^+^ T cells can be tolerized or receive a "license to kill."

![**Involvement of the XCL1--XCR1 communication axis in the innate and adaptive cytotoxic responses to cross-presented microbial and tumor antigens**. Secretion of the chemokine XCL1 by activated NK cells specifically attracts XCR1-expressing DCs capable of antigen cross-presentation. This ensures an effective communication between these cells in the innate phase of the immune response. In the adaptive phase, secretion of XCL1 by activated CD8^+^ T cells optimizes the dialog with antigen cross-presenting DCs and facilitates the differentiation of CD8^+^ T cells to cytotoxic effector cells.](fimmu-03-00014-g001){#F1}

One additional factor in this complex interplay may be the special capacity of XCR1^+^ DCs to take up certain forms of antigen. Uptake of *L. monocytogenes* by CD8^+^ DCs (which now have to be reconsidered as XCR1^+^ DCs) is critical for infection with *Listeria* (Neuenhahn et al., [@B29]; Edelson et al., [@B16]), and possibly also for the development of immunity against this pathogen. Thus, the special ability of XCR1^+^ DCs to take up certain (intracellular?) pathogens defines them as ideal DCs for instructing cytotoxic effector cells of the innate and adaptive immune systems to eliminate infected cells in the periphery. This mechanism appears important, since pathogens, once "hidden" in infected cells, are otherwise "invisible" to the immune system. A similar function of XCR1^+^ DCs can be hypothesized in the surveillance of the body for tumor antigens. Live or dead cancerous cells taken up by XCR1^+^ DCs will be digested and processed, and any tumor antigens will be cross-presented by the MHC-class I molecules to CD8^+^ T cells. One has to assume, however, that the recognition of "altered self" from cancerous tissue by CD8^+^ T cells has to be accompanied by some "adjuvant" signal to initiate a cytotoxic response against the tumor. Otherwise, a tolerance reaction to "altered self" may result.

The exquisite specificity of XCR1 expression may in future be exploited for vaccination purposes. Almost a decade ago, the groups of Steinman and Nussenzweig had pioneered the concept of antigen targeting to DCs by employing a mAb directed to CD205 (Hawiger et al., [@B17]). Such a concept promises to lower the antigen dose required to induce optimal immunity. More importantly, by targeting antigen to functionally different DC subsets, it offers the possibility to elicit *highly specific* immune responses. Based on such a concept, one can envisage future "designer vaccines" which address various components of the immune system to a different extent and thus elicit a protective immune response tailored to given pathogens. Early studies employing antibodies directed to CD205 convincingly demonstrated that potent cytotoxic CD8^+^ T cell immunity can be induced when the targeted antigen is administered together with agents having adjuvant activity on DCs (Bonifaz et al., [@B5]). Similar results were obtained later with mAb directed to Clec9A/DNGR-1 (Caminschi et al., [@B6]; Sancho et al., [@B33]). None of the mAb used for DC-targeted antigen delivery to date, however, recognizes only one functional DC subset. For example, CD205 in the mouse is expressed on a variety of cells, including B cells, as well as thymic and intestinal epithelia (Witmer-Pack et al., [@B37]), Clec9A/DNGR-1 on pDCs, and a subset of CD24^+^ blood DCs (Caminschi et al., [@B6]; Sancho et al., [@B33]). This may not be disadvantageous for the induction of the desired immune response, but the lack of "absolute" specificity for a functional DC subset runs against the "designer vaccine" concept, in which only one component of the immune system is specifically addressed. Thus, ideally, antigen could be selectively delivered to B cells, or pDCs, or any of the functionally different DC subsets (or any desired combination thereof). XCR1 as a target molecule appears to fulfill such an ideal. By being expressed only on the subset of DCs preferentially interacting with components of cytotoxic immunity (NK cells and CD8^+^ T cells), it holds the promise of an entry port for vaccines against intracellular pathogens like *P. falciparum* or *M. tuberculosis*. Initial targeting tests performed with OVA recombinantly engineered to the chemokine ligand XCL1 or with OVA chemically coupled to the XCR1-specific mAb MARX10 gave very promising results. By combining this type of antigen delivery with adjuvants, a potent and specific *in vivo* cytotoxicity could be achieved (own unpublished results). Further tests have to be performed, however, to demonstrate that this response is highly selective and does not address other components of the immune system. Thus, XCR1 appears as an attractive target molecule for the "designer vaccine" concept.

All antigen targeting experiments were performed in the mouse and have to be regarded as model systems only. In the human system, the phenotype and function of DCs is less well understood, since most of the data has been obtained with *in vitro* generated monocyte-derived DCs, which may only partially reflect DC function *in vivo*. In the relatively few studies with primary human DCs, CD304^+^ pDCs, and conventional DCs encompassing the CD1c^+^ (BDCA-1^+^), CD16^+^, and CD141^+^ DC (BDCA-3^+^) subsets could be identified in the peripheral blood (Dzionek et al., [@B15]; MacDonald et al., [@B26]; Piccioli et al., [@B31]; for review see Ju et al., [@B23]). Extensive gene expression comparison suggested that CD141^+^ DCs may correspond to murine CD8^+^ DCs (Robbins et al., [@B32]). Recent experimental work has confirmed this hypothesis: XCR1 was found to be selectively expressed in CD141^+^ DCs and not in other cells (Bachem et al., [@B1]; Crozat et al., [@B7]), and CD141^+^ DCs were the only DC subset migrating to XCL1 (Bachem et al., [@B1]). Further, primary CD141^+^ DCs were found to be particularly capable of antigen cross-presentation, when tested *in vitro* with soluble or cell-associated antigen (Bachem et al., [@B1]; Crozat et al., [@B7]; Jongbloed et al., [@B22]). These data collectively indicated that CD141^+^ DCs are the homologs of murine CD8^+^ DCs and suggest that the lessons learned in the mouse most likely will also hold true in the human. This view is supported by the close structural resemblance of mouse and human XCL1 and mouse and human XCR1. Moreover, the expression pattern of human XCL1 (activated NK cells and CD8^+^ T cells; Müller et al., [@B28]; Hedrick et al., [@B18]; Blaschke et al., [@B3]) appears very similar to the XCL1 expression profile in the mouse. Thus, the CD141^+^ DCs are most likely specialized on the surveillance of intracellular pathogens and also aberrant antigens originating from cancerous tissue. Similar to the mouse system, they can be expected to closely cooperate with cells of cytotoxic immunity.

Considering all available functional data, XCR1 also in the human appears to be an ideal target for antigen delivery. Different from CD205, which in the human is expressed on CD11c^+^ DC, monocytes, pDC, NK cells, and T cells (Kato et al., [@B24]), and Clec9A/DNGR-1, which is expressed on CD141^+^ DC, but also found on a subset of B cells and CD14^+^ CD16^−^ monocytes (Caminschi et al., [@B6]; Huysamen et al., [@B20]), expression of XCR1 is restricted to CD141^+^ DCs. Given this selectivity and the functional association with antigen cross-presentation, XCR1 emerges as a prime candidate for vaccines designed to induce selective cytotoxic immunity in man.
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